CureDuchenne is pleased to share the following information from Sarepta Therapeutics. They provided a summary of the regulatory developments and clinical updates.
Sarepta is dedicated to helping DMD patients and their families, and we are committed to working as fast as possible to move our eteplirsen and follow-on DMD programs forward. We know the patient community is interested in our regulatory and clinical progress, so we have outlined our latest developments below. We have multiple studies that we plan to enroll soon, and we remain steadfast in our efforts to address this devastating disease. Read more.